A molecular screening strategy based on β-myosin heavy chain, cardiac myosin binding protein C and troponin T genes in Italian patients with hypertrophic cardiomyopathy

Background Mutations causing hypertrophic cardiomyopathy (HCM) have been described in nine different genes of the sarcomere. Three genes account for most known mutations: β-myosin heavy chain (MYH7), cardiac myosin binding protein C (MYBPC3) and cardiac troponin T (TNNT2). Their prevalence in Italian HCM patients is unknown. Thus, we prospectively assessed a molecular screening strategy of these three genes in a consecutive population with HCM from two Italian centres. Methods Comprehensive screening of MYBPC3, MYH7 and TNNT2 was performed in 88 unrelated HCM patients by denaturing high-performance liquid chromatography and automatic sequencing. Results We identified 32 mutations in 50 patients (57%); 16 were novel. The prevalence rates for MYBPC3, MYH7 and TNNT2 were 32%, 17% and 2%, respectively. MYBPC3 mutations were 18, including two frameshift, five splice-site and two nonsense. All were ‘private’ except insC1065 and R502Q, present in three and two patients, respectively. Moreover, E258K was found in 14% of patients, suggesting a founder effect. MYH7 mutations were 12, all missense; seven were novel. In TNNT2, only two mutations were found. In addition, five patients had a complex genotype [i.e. carried a double MYBPC3 mutation (n = 2), or were double heterozygous for mutations in MYBPC3 and MYH7 (n = 3)]. Conclusions The first comprehensive evaluation of MYBPC3, MYH7 and TNNT2 in an Italian HCM population allowed a genetic diagnosis in 57% of the patients. These data support a combined analysis of the three major sarcomeric genes as a rational and cost-effective initial approach to the molecular screening of HCM.

[1]  A. Gavazzi,et al.  The Italian Registry for hypertrophic cardiomyopathy: a nationwide survey. , 2005, American heart journal.

[2]  M. Link,et al.  Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[3]  A. Tajik,et al.  Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[4]  R. Jeremy,et al.  Denaturing high performance liquid chromatography: high throughput mutation screening in familial hypertrophic cardiomyopathy and SNP genotyping in motor neurone disease , 2005, Journal of Clinical Pathology.

[5]  A. Tajik,et al.  Sarcomeric genotyping in hypertrophic cardiomyopathy. , 2005, Mayo Clinic proceedings.

[6]  Masahiko Hoshijima,et al.  Tcap gene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy. , 2004, Journal of the American College of Cardiology.

[7]  A. Tajik,et al.  Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. , 2004, Journal of the American College of Cardiology.

[8]  A. Tajik,et al.  Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy. , 2004, Journal of the American College of Cardiology.

[9]  M. Komajda,et al.  Calcified mediastinal haematoma: a rare case of cardiac constriction , 2004, Heart.

[10]  B. Giusti,et al.  Improvement of low-density microelectronic array technology to characterize 14 mutations/single-nucleotide polymorphisms from several human genes on a large scale. , 2004, Clinical chemistry.

[11]  M. Laakso,et al.  Genetics of hypertrophic cardiomyopathy in eastern Finland: few founder mutations with benign or intermediary phenotypes , 2004, Annals of medicine.

[12]  L. Mestroni,et al.  Familial hypertrophic cardiomyopathy: clinical features, molecular genetics and molecular genetic testing , 2004, Expert review of molecular diagnostics.

[13]  F. Girolami,et al.  Prevalence and clinical profile of troponin T mutations among patients with hypertrophic cardiomyopathy in tuscany. , 2003, The American journal of cardiology.

[14]  C. Tracy,et al.  American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G , 2003, European heart journal.

[15]  V. Regitz-Zagrosek,et al.  The 2373insG mutation in the MYBPC3 gene is a founder mutation, which accounts for nearly one-fourth of the HCM cases in the Netherlands. , 2003, European heart journal.

[16]  V. Regitz-Zagrosek,et al.  Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy , 2003, Clinical genetics.

[17]  I. Olivotto,et al.  Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. , 2003, The New England journal of medicine.

[18]  I. Olivotto,et al.  The epidemiologic evolution and present perception of hypertrophic cardiomyopathy. , 2003, Italian heart journal : official journal of the Italian Federation of Cardiology.

[19]  Ferhaan Ahmad,et al.  Transgenic Mice Overexpressing Mutant PRKAG2 Define the Cause of Wolff-Parkinson-White Syndrome in Glycogen Storage Cardiomyopathy , 2003, Circulation.

[20]  A. Marian,et al.  To screen or not is not the question--it is when and how to screen. , 2003, Circulation.

[21]  M. Komajda,et al.  Hypertrophic Cardiomyopathy: Distribution of Disease Genes, Spectrum of Mutations, and Implications for a Molecular Diagnosis Strategy , 2003, Circulation.

[22]  R. Dietz,et al.  Mutations in the Human Muscle LIM Protein Gene in Families With Hypertrophic Cardiomyopathy , 2003, Circulation.

[23]  B. Maron,et al.  Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. , 2003, The New England journal of medicine.

[24]  M. Komajda,et al.  Genetic testing and genetic counselling in hypertrophic cardiomyopathy: the French experience , 2002, Journal of medical genetics.

[25]  A. Tajik,et al.  Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a comprehensive outpatient perspective. , 2002, Journal of the American College of Cardiology.

[26]  P. Elliott,et al.  Prevalence of Anderson-Fabry Disease in Male Patients With Late Onset Hypertrophic Cardiomyopathy , 2002, Circulation.

[27]  B. Maron.  Hypertrophic cardiomyopathy: a systematic review. , 2002, JAMA.

[28]  P. Oefner,et al.  Denaturing high‐performance liquid chromatography: A review , 2001, Human mutation.

[29]  H. Watkins,et al.  Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. , 2001, Human molecular genetics.

[30]  A. Marian,et al.  The molecular genetic basis for hypertrophic cardiomyopathy. , 2001, Journal of molecular and cellular cardiology.

[31]  B. Maron,et al.  Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. , 2000, Circulation.

[32]  R. Cotton,et al.  Quality control in the discovery, reporting, and recording of genomic variation , 2000, Human mutation.

[33]  M. Yacoub,et al.  Genomic organisation, alternative splicing and polymorphisms of the human cardiac troponin T gene. , 1998, Journal of molecular and cellular cardiology.

[34]  H Niimura,et al.  Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. , 1998, The New England journal of medicine.

[35]  M. Komajda,et al.  Organization and sequence of human cardiac myosin binding protein C gene (MYBPC3) and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy. , 1997, Circulation research.

[36]  E. Ricci,et al.  Maternally inherited cardiomyopathy: A new phenotype associated with the A to G at nt.3243 of mitochondrial DNA (MELAS mutation) , 1997, Muscle & nerve.

[37]  B. Maron,et al.  Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. , 1995, Journal of the American College of Cardiology.

[38]  J. Gardin,et al.  Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. , 1995, Circulation.